Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Combining darolutamide (Nubeqa) with androgen deprivation therapy (ADT) showed improvements in efficacy vs placebo plus ADT among patients with metastatic hormone-sensitive prostate cancer (HSPC) who were 75 years or older, according to subgroup…